Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy.

ABSTRACT:

Aim

Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leading to therapeutic failure. This study aimed to identify key differences in gene expression profile in tumors from chemoresponsive and chemoresistant patients.

Methods

Archived formalin-fixed paraffin-embedded tumor tissue samples from patients treated with neoadjuvant chemotherapy were obtained during surgical resection. Specimens were macrodissected and gene expression analysis was performed. Multi- and univariate statistical analysis was performed to identify differential gene expression profile of tumors from good (0%-30% residual viable tumor [RVT]) and poor (>30% RVT) c

SUBMITTER: Sahni S 

PROVIDER: S-EPMC10523964 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature